Upgrade for Complete Access See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Merck
Express Scripts
Boehringer Ingelheim
AstraZeneca
Baxter

Last Updated: December 6, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR LAROTRECTINIB

➤ Subscribe for complete access

« Back to Dashboard

All Clinical Trials for Larotrectinib

Trial ID Title Status Sponsor Phase Start Date Summary
NCT02122913 ↗ A Study to Test the Safety of the Investigational Drug Larotrectinib in Adults That May Treat Cancer Completed Bayer Phase 1 2014-05-04 This research study is done to test the safety of the drug larotrectinib in adult cancer patients. The drug may be used to treat cancer with a change in a particular gene (NTRK1, NTRK2 or NTRK3), because it blocks the action of these genes in cancer cells. The study also investigates how the drug is absorbed and processed in the human body. This is the first study to test larotrectinib in humans with cancer, for whom no other effective therapy exists.
NCT02122913 ↗ A Study to Test the Safety of the Investigational Drug Larotrectinib in Adults That May Treat Cancer Completed Loxo Oncology, Inc. Phase 1 2014-05-04 This research study is done to test the safety of the drug larotrectinib in adult cancer patients. The drug may be used to treat cancer with a change in a particular gene (NTRK1, NTRK2 or NTRK3), because it blocks the action of these genes in cancer cells. The study also investigates how the drug is absorbed and processed in the human body. This is the first study to test larotrectinib in humans with cancer, for whom no other effective therapy exists.
NCT02465060 ↗ Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) Recruiting National Cancer Institute (NCI) Phase 2 2015-08-12 This phase II MATCH trial studies how well treatment that is directed by genetic testing works in patients with solid tumors or lymphomas that have progressed following at least one line of standard treatment or for which no agreed upon treatment approach exists. Genetic tests look at the unique genetic material (genes) of patients' tumor cells. Patients with genetic abnormalities (such as mutations, amplifications, or translocations) may benefit more from treatment which targets their tumor's particular genetic abnormality. Identifying these genetic abnormalities first may help doctors plan better treatment for patients with solid tumors, lymphomas, or multiple myeloma.
NCT02576431 ↗ A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors Recruiting Bayer Phase 2 2015-09-30 This research study is done to test how well different types of cancer respond to the drug called larotrectinib. The cancer must have a change in a particular gene (NTRK1, NTRK2 or NTRK3). Larotrectinib is a drug that blocks the actions of these NTRK genes in cancer cells and can therefore be used to treat cancer.
NCT02576431 ↗ A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors Recruiting Loxo Oncology, Inc. Phase 2 2015-09-30 This research study is done to test how well different types of cancer respond to the drug called larotrectinib. The cancer must have a change in a particular gene (NTRK1, NTRK2 or NTRK3). Larotrectinib is a drug that blocks the actions of these NTRK genes in cancer cells and can therefore be used to treat cancer.
NCT02637687 ↗ A Study to Test the Safety and Efficacy of the Drug Larotrectinib for the Treatment of Tumors With NTRK-fusion in Children Recruiting Bayer Phase 1/Phase 2 2015-12-16 The study is being done to test the safety of a cancer drug called larotrectinib in children. The cancer must have a change in a particular gene (NTRK1, NTRK2 or NTRK3). Larotrectinib blocks the actions of these NTRK genes in cancer cells and can therefore be used to treat cancer. The first study part (Phase 1) is done to determine what dose level of larotrectinib is safe for children, how the drug is absorbed and changed by their bodies and how well the cancer responds to the drug. The main purpose of the second study part (Phase 2) is to investigate how well and how long different cancer types respond to the treatment with larotrectininb.
NCT02637687 ↗ A Study to Test the Safety and Efficacy of the Drug Larotrectinib for the Treatment of Tumors With NTRK-fusion in Children Recruiting Loxo Oncology, Inc. Phase 1/Phase 2 2015-12-16 The study is being done to test the safety of a cancer drug called larotrectinib in children. The cancer must have a change in a particular gene (NTRK1, NTRK2 or NTRK3). Larotrectinib blocks the actions of these NTRK genes in cancer cells and can therefore be used to treat cancer. The first study part (Phase 1) is done to determine what dose level of larotrectinib is safe for children, how the drug is absorbed and changed by their bodies and how well the cancer responds to the drug. The main purpose of the second study part (Phase 2) is to investigate how well and how long different cancer types respond to the treatment with larotrectininb.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Larotrectinib

Condition Name

Condition Name for Larotrectinib
Intervention Trials
Refractory Malignant Solid Neoplasm 3
Recurrent Malignant Solid Neoplasm 3
Recurrent Glioma 3
Advanced Malignant Solid Neoplasm 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Larotrectinib
Intervention Trials
Neoplasms 7
Glioma 4
Nervous System Neoplasms 4
Central Nervous System Neoplasms 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Larotrectinib

Trials by Country

Trials by Country for Larotrectinib
Location Trials
United States 247
Canada 11
Italy 9
Australia 9
Japan 8
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Larotrectinib
Location Trials
Texas 10
Pennsylvania 9
Ohio 9
Washington 9
Tennessee 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Larotrectinib

Clinical Trial Phase

Clinical Trial Phase for Larotrectinib
Clinical Trial Phase Trials
Phase 2 7
Phase 1/Phase 2 1
Phase 1 2
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Larotrectinib
Clinical Trial Phase Trials
Recruiting 9
Completed 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Larotrectinib

Sponsor Name

Sponsor Name for Larotrectinib
Sponsor Trials
Bayer 4
National Cancer Institute (NCI) 4
Loxo Oncology, Inc. 3
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Larotrectinib
Sponsor Trials
Industry 16
Other 8
NIH 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
McKinsey
Medtronic
Colorcon
Johnson and Johnson
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.